Viking Therapeutics heats up competition in obesity with impressive Phase 2 data

Arctic Aurora portfolio company Viking Therapeutics opened nearly 100% up on positive weight loss data from a Phase 2 study

Obesity is one of the largest societal and healthcare burdens globally. It is estimated to affect more than 650 million people, who are at a higher risk of developing more than 200 health complications including diabetes, cardiovascular problems, and fatty liver disease. In the recent years, multiple drugs have been developed to address this global challenge.

Arctic Aurora LifeScience and Arctic Aurora Biotech Select portfolio company Viking Therapeutics is a strong contender in the obesity space. Today, they announced competitive Phase 2 results of their drug candidate, VK2735. Obese patients in the trial achieved a placebo-adjusted weight loss of up to 13.1% after just 13 weeks. Importantly, weight loss did not plateau at 13 weeks and the treatment was effective in most patients with 88% of them achieving a ≥10% weight loss at the end of the trial. The side effects of the drug were comparable to other similar treatments.

VK2735 is a dual activator of the glucagon-like-peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors. Effect on these receptors is associated with reduced body weight and appetite, and higher sensitivity to insulin. Among the drugs that are already approved, semaglutide (brand name Ozempic/Wegovy, marketed by Novo Nordisk) acts on GLP-1 while tirzepatide (Mounjaro/Zepbound by Eli Lilly) is a dual activator of the GLP-1/GIP receptors similarly to VK2735. According to consensus, the size of the obesity market will reach USD 100-150 billion and the peak sales of semaglutide and tirzepatide are expected to be USD 40 billion and USD 45 billion, respectively.

Viking270224

Latest news

  1. Arctic Asset Management -

    Markedskommentar Juni 2024

    Aksjemarkedet hadde en positiv utvikling i mai, hvor Oslo Børs ledet an med en oppgang på 5,2% hjulpet av en bred oppgang i råvarepriser og fortsatt god fart i shipping. Globalt steg verdensindeksen målt ved MSCI World Index (NOK) med 3,9% og det amerikanske aksjemarkedet steg 4,8% (S&P 500 USD). 

    Read more →
  2. Arctic Asset Management -

    Arctic Midt i Måneden

    Arctic Global Select - Det nye fondet "alle" snakker om

    Albert Collett har fått besøk i studio av forvalter, Tone Varmann, som forteller om det nye fondet «Arctic Global Select». Et globalt og aktivt forvaltet aksjefond i samarbeid med “glokale” spesialister.

    Hør hvordan Tone bygger et globalt forvalterteam, med sektorspesialister i de mest disruptive delene av markedet som komplementerer hverandre gjennom skiftende markedsforhold. – og hvem det nye aksjefondet, Arctic Global Select, passer for.

    Read more →
  3. Arctic Asset Management -

    Markedskommentar Mai 2024

    Aksjemarkedet hadde en positiv utvikling i mai, hvor Oslo Børs ledet an med en oppgang på 5,2% hjulpet av en bred oppgang i råvarepriser og fortsatt god fart i shipping. Globalt steg verdensindeksen målt ved MSCI World Index (NOK) med 3,9% og det amerikanske aksjemarkedet steg 4,8% (S&P 500 USD). 

    Read more →
  5. Arctic Asset Management -

    Biotech hitting the news

    This morning, Ulrica Slåne Bjerke, portfolio manager and CIO for our healthcare funds Arctic Aurora LifeScience and Biotech Select, was invited to Dagens Industri’s TV Börsmorgon. She commented on topics currently in focus regarding the sector, obesity stocks Novo and Lilly, falling interest rates positive for biotech, Novavax share price soaring as well as some Swedish med tech companies having an uphill day.

    Read more →